Related Experiment Video
Updated: May 10, 2025

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
Voriconazole-induced cholestatic hepatotoxicity in fungal pneumonia
Mahima Gupta1, Manjunath Bidarolli2, Npk Teja3
1Department of Pharmacology, All India Institute of Medical Sciences Rishikesh Department of Pharmacology, Rishikesh, Uttarakhand, India mahima.jr@aiimsrishikesh.edu.in.
Abstract:
Voriconazole is a widely used antifungal agent for invasive aspergillosis; however, hepatotoxicity is a significant concern. While hepatocellular toxicity is well documented, cholestatic liver injury remains relatively rare. We report a case of voriconazole-induced cholestatic hepatotoxicity in a patient with fungal pneumonia. The patient developed elevated alkaline phosphatase and gamma-glutamyl transpeptidase levels beyond the therapeutic range. Voriconazole was discontinued, and the patient was switched to posaconazole, leading to a decline in cholestatic markers. This report underscores the importance of therapeutic drug monitoring and highlights posaconazole as a safer alternative in patients experiencing voriconazole-induced hepatotoxicity.
More Related Videos
Related Concept Videos
Hepatic Drug Excretion: Influencing Factors
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Pneumonia III: Complications and Assessment

